Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Data Science”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,783 records · Page 99Linked to original sources
PubMed2005

Data reduction in headspace analysis of blood and urine samples for robust bacterial identification.

This paper demonstrates the application of chemical headspace analysis to the problem of classifying the presence of bacteria in biomedical samples by using computational tools. Blood and urine samples of disparate forms were analysed using a Cyrano Sciences C320 electronic nose together with an Agilent 4440 Chemosensor. The high dimensional data sets resulting from these devices present computational problems for parameter estimation of discriminant models. A variety of data reduction and pattern recognition techniques were employed in an attempt to optimise the classification process. A 100% successful classification rate for the blood data from the Agilent 4440 was achieved by combining a Sammon mapping with a radial basis function neural network. In comparison a successful classification rate of 80% was achieved for the urine data from the C320 which were analysed using a novel nonlinear time series model.

Bacteremia↗
PubMed2001

Beyond the genome: turning data into knowledge.

Since the publication of the draft sequence of the human genome in April 2001 (1,2), the pressure on life scientists to annotate and gain useful knowledge from the millions of As, Gs, Cs and Ts, is ever increasing. Now that the initial hype has passed, the life sciences field demands the technologies and computer power that can produce and analyze data in a high-throughput manner for drug discovery and disease diagnosis. Cambridge Healthtech Institute's Beyond Genome 2001 conference(1) (17-22 June 2001, San Francisco, CA, USA) brought together the latest research in these technologies in a 'tri-conference' that encompassed the 10th Annual Conference of Bioinformatics and Genome Research, the 3rd Annual Conference of In Silico Biology and the 5th Annual Conference of Proteomics.

Journal Article↗
PubMed1995

NASA high performance computing, communications, image processing, and data visualization-potential applications to medicine.

High-speed information processing technologies being developed and applied by the Jet Propulsion Laboratory for NASA and Department of Defense mission needs have potential dual-uses in telemedicine and other medical applications. Fiber optic ground networks connected with microwave satellite links allow NASA to communicate with its astronauts in Earth orbit or on the moon, and with its deep space probes billions of miles away. These networks monitor the health of astronauts and or robotic spacecraft. Similar communications technology will also allow patients to communicate with doctors anywhere on Earth. NASA space missions have science as a major objective. Science sensors have become so sophisticated that they can take more data than our scientists can analyze by hand. High performance computers--workstations, supercomputer and massively parallel computers are being used to transform this data into knowledge. This is done using image processing, data visualization and other techniques to present the data--one's and zero's in forms that a human analyst can readily relate to and understand. Medical sensors have also explored in the in data output--witness CT scans, MRI, and ultrasound. This data must be presented in visual form and computers will allow routine combination of many two dimensional MRI images into three dimensional reconstructions of organs that then can be fully examined by physicians. Emerging technologies such as neural networks that are being "trained" to detect craters on planets or incoming missiles amongst decoys can be used to identify microcalcification in mammograms.

Image Interpretation, Computer-Assisted↗
PubMed1994

NASA's Space Life Sciences Training Program.

The Space Life Sciences Training Program (SLSTP) is an intensive, six-week training program held every summer since 1985 at the Kennedy Space Center (KSC). A major goal of the SLSTP is to develop a cadre of qualified scientists and engineers to support future space life sciences and engineering challenges. Hand-picked, undergraduate college students participate in lectures, laboratory sessions, facility tours, and special projects: including work on actual Space Shuttle flight experiments and baseline data collection. At NASA Headquarters (HQ), the SLSTP is jointly sponsored by the Life Sciences Division and the Office of Equal Opportunity Programs: it has been very successful in attracting minority students and women to the fields of space science and engineering. In honor of the International Space Year (ISY), 17 international students participated in this summer's program. An SLSTP Symposium was held in Washington D.C., just prior to the World Space Congress. The Symposium attracted over 150 SLSTP graduates for a day of scientific discussions and briefings concerning educational and employment opportunities within NASA and the aerospace community. Future plans for the SLSTP include expansion to the Johnson Space Center in 1995.

Biological Science Disciplines↗
PubMed1989

Mapping population data from zone centroid locations.

The author describes the difficulties associated with the use of maps to represent census data. "A review of the problems associated with population mapping is followed by a discussion of [an alternative method known as] a raster method for handling census data, based on population-weighted centroids, and its implications for GIS "[geographic information systems]." The geographical scope is worldwide, with an example provided using data for Wales.

Developed Countries↗
PubMed2006

Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.

OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical trial data, safety profile, precautions, and place in therapy of febuxostat, a novel nonpurine xanthine oxidase inhibitor in development for the treatment of hyperuricemia and gout. DATA SOURCES: Available studies and abstracts were identified through MEDLINE (1990-November 2006), Science Citation Index, International Pharmaceutical Abstracts, Cochrane Databases, and the American College of Rheumatology and European League Against Rheumatism Web sites. Key search terms were febuxostat, TMX-67, TEI-6720, hyperuricemia, and gout. STUDY SELECTION AND DATA EXTRACTION: All available studies describing the pharmacology of febuxostat were included. Human studies formed the basis for discussion of clinical parameters, including pharmacokinetics, pharmacodynamics, efficacy, and safety of febuxostat. DATA SYNTHESIS: Febuxostat significantly reduces uric acid levels within 2 weeks after initiation of therapy and up to 48% by the end of 104 weeks of therapy. Approximately 60% of patients achieved the primary goal of serum uric acid less than 6 mg/dL during the last 3 months following once-daily administration of febuxostat 80 mg or 120 mg for at least 52 weeks. The most common adverse reactions to febuxostat were abnormal results from liver function tests, diarrhea, headache, arthralgias, and musculoskeletal symptoms. Due to its potency, patients are at an increased risk of experiencing gout flares for at least the first year of therapy. Up to 70% of patients in clinical trials experienced gout flares despite concomitant prophylactic treatment with colchicine or naproxen. Additional clinical trial evidence supports the efficacy and safety of febuxostat in the treatment of hyperuricemia and gout. CONCLUSIONS: Febuxostat is a promising alternative to allopurinol for the treatment of gout and hyperuricemia. The optimal length of prophylactic therapy, clinical significance of abnormal liver function tests results during therapy, and safety in patients with moderate or severe renal insufficiency warrant further investigation.

Febuxostat↗
PubMed2006

Assessment of the prevalence and costs of osteoporosis treatment options in a real-world setting.

Osteoporosis-related nonvertebral fractures increase the risks for morbidity and mortality and add substantially to treatment costs. As an adjunct to controlled, clinical trials, observational studies based on information from large, integrated medical and pharmaceutical claims databases provide an opportunity to assess the "real-world" cost effectiveness of treatment options aimed at reducing osteoporotic fracture risk. Although they lack the stringent controls required to establish causation, these studies include a large treatment population that reflects current disease prevalence, prescribing practices, and treatment-cost patterns in the managed care setting. This article reviews data from key observational studies that used analyses of the large Protocare Sciences Integrated Medical and Pharmaceutical Claims Database, which includes claims and eligibility records for >3 million individuals covered annually under various public and private benefit plans, to explore the cost effectiveness of oral bisphosphonates--risedronate and alendronate--in reducing the risk for nonvertebral fracture. In addition, the data from the Protocare database were used to examine the cost implications of differences in gastrointestinal tolerability in these agents.

Cost-Benefit Analysis↗
PubMed2003

[Thiamine Hydrochloride Solution Reference Standard (Control 021) of National Institute of Health Sciences].

The raw material of thiamine hydrochloride was examined for preparation of the "Thiamine Hydrochloride Reference Standard". The analytical data obtained were: assay by HPLC, 100.5%; spectrophotometric assay 101.2%. Based on the above results, the candidate material was authorized as the Thiamine Hydrochloride Reference Standard (Control 021) of the National Institute of Health Sciences.

Chromatography, High Pressure Liquid↗
PubMed1998

Treatment of acute otitis media with a shortened course of antibiotics: a meta-analysis.

OBJECTIVE: To conduct a meta-analysis of randomized controlled trials of antibiotic treatment of acute otitis media in children to determine whether outcomes were comparable in children treated with antibiotics for less than 7 days or at least 7 days or more. DATA SOURCES: MEDLINE (1966-1997), EMBASE (1974-1997), Current Contents, and Science Citation Index searches were conducted to identify randomized controlled trials of the treatment of acute otitis media in children with antibiotics of different durations. STUDY SELECTION: Studies were included if they met the following criteria: subjects aged 4 weeks to 18 years, clinical diagnosis of acute otitis media, no antimicrobial therapy at time of diagnosis, and randomization to less than 7 days of antibiotic treatment vs 7 days or more of antibiotic treatment. DATA EXTRACTION: Trial methodological quality was assessed independently by 7 reviewers; outcomes were extracted as the number of treatment failures, relapses, or reinfections. DATA SYNTHESIS: Included trials were grouped by antibiotic used in the short course: (1) 15 short-acting oral antibiotic trials (penicillin V potassium, amoxicillin [-clavulanate], cefaclor, cefixime, cefuroxime, cefpodoxime proxetil, cefprozil), (2) 4 intramuscularceftriaxone sodium trials, and (3) 11 oral azithromycin trials. The summary odds ratio for treatment outcomes at 8 to 19 days in children treated with short-acting antibiotics for 5 days vs 8 to 10 days was 1.52 (95% confidence interval [CI], 1.17-1.98) but by 20 to 30 days outcomes between treatment groups were comparable (odds ratio, 1.22; 95% CI, 0.98 to 1.54). The risk difference (2.3%; 95% CI,-0.2% to 4.9%) at 20 to 30 days suggests that 44 children would need to be treated with the long course of short-acting antibiotics to avoid 1 treatment failure. This similarity in later outcomes was observed for up to 3 months following therapy (odds ratio, 1.16; 95% CI, 0.90-1.50). Comparable outcomes were shown between treatment with ceftriaxone or azithromycin, and at least 7 days of other antibiotics. CONCLUSION: This meta-analysis suggests that 5 days of short-acting antibiotic use is effective treatment for uncomplicated acute otitis media in children.

Acute Disease↗
PubMed2001

Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials.

CONTEXT: Hepatitis C is the leading cause of chronic liver disease in the United States. Several trials have found that interferon and ribavirin combination therapy is more efficacious than interferon monotherapy for previously untreated patients and those who relapsed after prior interferon monotherapy, but its effectiveness for nonresponders to prior interferon monotherapy is unclear. OBJECTIVE: To assess the efficacy and safety of interferon and ribavirin vs interferon alone for treatment of patients with chronic hepatitis C who previously did not respond to interferon monotherapy. DATA SOURCES: A systematic search was performed using MEDLINE and the Science Citation Index for publications from 1966 to December 1999. A manual reference search and a manual review of relevant specialty journals also were performed, and input from clinical hepatology experts was sought. STUDY SELECTION: Included studies were randomized, controlled clinical trials comparing interferon and ribavirin with interferon alone and reporting virological and biochemical outcomes after a follow-up period. Of 50 identified studies, 12 trials (941 patients) were included in the analysis. DATA EXTRACTION: Two investigators reviewed trials independently for methods, inclusion and exclusion criteria, and outcomes. Disagreements were resolved by discussion. Abstracted data included study and patient characteristics and virological, biochemical, and histological outcomes. A quality evaluation questionnaire was used to score studies. DATA SYNTHESIS: The pooled virological response rate for combination therapy was 14% (95% confidence interval [CI], 11%-17%), with a risk difference favoring combination therapy of 7% (95% CI, 2%-13%). Use of interferon alfa-2a/2b and ribavirin, 1000 to 1200 mg/d, was associated with a pooled virological response rate of 18% and a risk difference of 16% (95% CI, 11%-21%). When interferon alfa-n/n3 and a lower dosage of ribavirin (600-800 mg/d) were used, the risk difference was 0% (95% CI, -7% to 7%). Combination therapy was associated with more adverse effects and an increased rate of discontinuation of treatment compared with interferon monotherapy. CONCLUSIONS: For chronic hepatitis C that is nonresponsive to prior interferon monotherapy, combination therapy is more effective than re-treatment with interferon alone. Response rates remain less than 20% even in the most responsive subgroups, demonstrating a need for better therapeutic options.

Antiviral Agents↗
PubMed2003

Survey of Listeria monocytogenes in ready-to-eat foods.

The purpose of this study was to develop data on the risk of listeriosis to support a science-based strategy for addressing Listeria monocytogenes in foods in the United States. Eight categories of ready-to-eat foods were collected over 14 to 23 months from retail markets at Maryland and northern California FoodNet sites. The product categories included luncheon meats, deli salads, fresh soft "Hispanic-style" cheeses, bagged salads, blue-veined and soft mold-ripened cheeses, smoked seafood, and seafood salads. The presence and levels of L. monocytogenes in the samples were determined by rapid DNA-based assays in combination with culture methods. Of 31,705 samples tested, 577 were positive. The overall prevalence was 1.82%. with prevalences ranging from 0.17 to 4.7% among the product categories. L. monocytogenes levels in the positive samples varied from <0.3 MPN (most probable number) per g to 1.5 x 10(5) CFU/g, with 402 samples having levels of <0.3 MPN/g, 21 samples having levels of >10(2) CFU/g, and the rest of the samples having intermediate levels. No obvious trends with respect to seasonality were observed. Significant differences (P < 0.05) between the sampling sites were found, with higher prevalences for threes categories in northern California and for two categories in Maryland. Significantly (P < 0.001) higher prevalences were found for in-store-packaged samples than for manufacturer-packaged samples of luncheon meats, deli salads, and seafood salads, while 16 of the 21 samples with higher counts were manufacturer packaged. The data collected in this study help to fill gaps in the knowledge about the occurrence of L. monocytogenes in foods, and this new information should be useful in the assessment of the risk posed by L. monocytogenes to consumers.

Animals↗